Selective serotonin reuptake inhibitors (SSRIs) selectively inhibit the reuptake of serotonin (5-hydroxytryptamine, 5-HT) in central nervous system (CNS) synapses, thus increasing the intra-synaptic concentration of serotonin.
Contra-indications
Use in children and adolescents [18] The Committee on Safety of Medicines (CSM) advises that balance of risks and benefits for the treatment of depressive illness in individuals aged <18 years is unfavourable for the SSRIs citalopram, escitalopram, paroxetine and sertraline [19] . They may be used by specialists, with close supervision for suicidal behaviour, self-harm or hostility. Fluoxetine has shown some benefit but there may be increased risk of self-harm and suicidal thoughts in individuals. Careful observation and monitoring are advised.
A meta-analysis of a number of trials of SSRIs in children suggests that the benefits of SSRIs appear to outweigh any suicidal risks in a number of conditions including depression and anxiety disorders [20] . Furthermore, the use of SSRIs in children is associated with a number of problems of which increased activity is prominent [21] .
Mania
SSRIs should be discontinued or avoided in patients displaying active manic symptoms.
Cautions
History of mania. Epilepsy -there is the need to weigh up the risks and benefits; avoid if poorly controlled and discontinue if there is deterioration; seek specialist advice if necessary. Fluoxetine is reported to prolong seizure duration with concurrent electroconvulsive therapy (ECT). Cardiac disease -however, SSRIs (such as sertraline) are probably the safest antidepressants in cardiac disease [22] . Acute angle-closure glaucoma. Diabetes mellitus (monitor glycaemic control after initiation). Concomitant use with drugs that cause bleeding, gastrointestinal (GI) bleeding, or where there is history of GI bleeding [3, 23, 24] . Hepatic/renal impairment. Pregnancy and breast-feeding: seek specialist advice -eg, the National Teratology Information Service [25] (neonatal withdrawal syndrome, particularly with paroxetine) [26, 27] . Young adults (possible increased suicide risk) [28] . Suicidal ideation [28] .
Important interactions
With monoamine-oxidase inhibitors (MAOIs)/moclobemide: serious toxicity risk. If changing from an SSRI, an MAOI or moclobemide should not be started until: five weeks after stopping fluoxetine; two weeks after stopping sertraline; one week after other SSRIs. Also, more than five weeks should elapse if on high doses or there is chronic use of fluoxetine. If changing from an MAOI, do not start SSRIs until two weeks after stopping an MAOI (but after stopping moclobemide, SSRIs can be started the following day, as moclobemide has a short duration of action). There is a range of interactions with a number of drugs, particularly with psychiatric medications, including other antidepressants (including St John's wort (SJW)). The risk of serotonin syndrome is increased by interactions with other drugs and care should be taken to monitor for its symptoms when starting new therapies in those on SSRIs. It is worth checking for known interactions of the individual SSRI with other drugs when starting new treatments. SSRIs inhibit platelet function and thus interact with other antiplatelet agents -eg, aspirin, clopidogrel, glycoprotein IIb/IIIa inhibitors. This interaction appears to be beneficial in acute coronary syndromes but the risk of bleeding is increased [29] .
Problems
Minor sedation and antimuscarinic side-effects may occur but are usually less frequent and troublesome than with TCAs. GI side-effects such as nausea, vomiting, dyspepsia and constipation are quite common. Anorexia or increased appetite with weight gain may occur. Hypersensitivity reactions with rash may be encountered and discontinuation should be considered, as it may herald a vasculitis. Urticaria, angio-oedema, anaphylaxis, arthralgia, myalgia and photosensitivity may occur as idiosyncratic reactions. A range of minor CNS symptoms such as headache, insomnia, tremor and dizziness may occur. Hallucinations, drowsiness and convulsions have been reported (see the note on epilepsy under 'Cautions', above). Sexual dysfunction, including ejaculatory delay and anorgasmia may occur . Hyponatraemia may occur in the elderly with SSRIs and, less commonly, with other antidepressants. It is thought to be due to the syndrome of inappropriate antidiuretic hormone (ADH) secretion. CSM advises considering the diagnosis in all elderly patients on antidepressants who develop drowsiness, confusion or convulsions [3, 19] . Other side-effects include sweating, galactorrhoea, urinary retention, movement disorders and dyskinesias and cutaneous bleeding (purpura and ecchymoses). Increased risk of suicidal ideation is postulated but as yet unproven [28, 30] . Serotonin syndrome -this can occur with overdose or concurrent MAOI use. It includes altered mental state, autonomic dysfunction, and neuromuscular abnormalities [3, 31] . There may also be an increased tendency of apathy in elderly individuals treated with SSRIs, despite improvement of depression [32] . Similarly, some data suggest an increase in fracture risk in patients over the age of 50 years on SSRIs [33] .
Initiation and discontinuation Before starting SSRIs ensure that patients are aware that they may take a few weeks to work, that they must stop if they develop a rash and that they must obtain help if agitation/suicidal feelings occur. Patients should be reviewed 1-2 weeks after starting treatment. A trial of at least 4-8 weeks (six weeks in older patients) should be given before deciding to discontinue/change an agent. If there is partial response, allow another two weeks to decide if effective or not. There is little evidence to support the use of dose escalation in patients who do not respond to standard doses [34] . After remission of symptoms, continue for at least 4-6 months (12 months in the older patient). Maintenance treatment may be needed in those with recurrent depression.
'Withdrawal' symptoms
These may occur after stopping SSRIs. GI symptoms, 'chills', insomnia, hypomania, anxiety and restlessness may occur. Aim to reduce the dose gradually over about four weeks or so to try to avoid/ameliorate this. In patients who have taken the drug long-term, they may need six months or so to withdraw gradually.
Monitoring
As there is a potential risk of increased suicidal ideation in those taking SSRIs, it is a good idea to ask explicitly about these symptoms and to document them before initiating these agents, and when reviewing a patient on SSRIs.
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